gamma-aminobutyric acid
γ-aminobutyric acid (GABA), a naturally occurring substance, which is a product of decarboxylation of the amino acid glutamate mediated by the synthesizing enzyme glutamic acid decarboxylase. GABA is a major inhibitory neurotransmitter of the brain and acts mainly through the GABAA receptor (GABAAR). GABA is locally produced by the pancreatic beta cells. GABAARs are also expressed in various immune cells, including T-cells, peripheral blood mononuclear cells, and are known to exert immune-inhibitory effects. Recently was studied, that GABA has the potential in treatment of Type I Diabetes. Moreover, was shown, that GABA administration could enhance immunity under stress conditions. — NCATS
Clinical trial activity
13 trials · 20 clinical orgs · 0 marketing orgs
Earliest trial started Oct 1, 2016 (NCT02928328)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
SMILES
NCCCC(O)=O- Mol. weight
- 103.1198 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral
- Availability
- Prescription Only
Oral
Yes
Parenteral
Yes
Topical
No
Sources
- WikipediaGamma-Aminobutyric acid ↗
- NCATS2ACZ6IPC6I ↗
- ChEMBLCHEMBL580 ↗
Also known as
- gamma butyric acid
- glutamate
- lorazepam
- lorazepam
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06748989 | N/A | Feb 1, 2025 | FEMPHARMA Kft. |
| NCT06464172 | N/A | Oct 1, 2024 | University of Sherbrooke |
| NCT06864520 | N/A | Oct 25, 2023 | University of Genoa |
| NCT06755489 | N/A | Apr 17, 2023 | University of Pisa |
| NCT05221892 | Phase 4 | Nov 22, 2021 | Fundação Educacional Serra dos Órgãos |
| NCT04683640 | Phase 2 | Jan 4, 2021 | National Institute on Aging (NIA), University of Florida |
| NCT04303468 | N/A | Jun 1, 2020 | Agrico Research, Avebe, BASF, Wageningen University |
| NCT04857021 | N/A | Apr 14, 2019 | Amorepacific Corporation |
| NCT03635437 | Phase 1/Phase 2 (Phase 2) | Sep 5, 2018 | Diamyd, Uppsala University |
| NCT04144439 | Phase 4 | Jul 1, 2018 | Kafrelsheikh University, Tanta University |
| NCT03180632 | Phase 2 | Jun 1, 2017 | University of Montreal |
| NCT03090620 | Phase 4 | Mar 30, 2017 | American Academy of Clinical Toxicology, University of Colorado, Denver |
| NCT02928328 | N/A | Oct 1, 2016 | Aalborg University |
Organizations
Research & Development (20)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aalborg University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Agrico Research | For profit | 1 | 0 | 1 | 2020 |
| American Academy of Clinical Toxicology | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Amorepacific Corporation | For profit | 1 | 1 | 1 | 2019 |
| Avebe | For profit | 1 | 0 | 1 | 2020 |
| BASF | For profit | 1 | 0 | 1 | 2020 |
| Diamyd | For profit | 1 | 0 | 1 | 2018 |
| FEMPHARMA Kft. | For profit | 1 | 1 | 1 | 2025 |
| Fundação Educacional Serra dos Órgãos | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Kafrelsheikh University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| National Institute on Aging (NIA) | Government | 1 | 0 | 1 | 2021 |
| Tanta University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Colorado, Denver | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Florida | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Genoa | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Montreal | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Pisa | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Sherbrooke | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Uppsala University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Wageningen University | Academic/Hospital | 1 | 1 | 1 | 2020 |